Soglizin LX-4211 is a new oral diabetes drug developed by Sanofi and Lescon Pharmaceuticals. As a dual inhibitor of SGLT-1 and SGLT-2, the drug can reduce postprandial blood glucose, increase GLP-1 and promote urinary glucose excretion.
![1H-Pyrrolo[2,3-c]PYRIDINE-3-acetic Acid, 4-METHOXY-7-(3-Methyl-1H-1,2,4-TRIAZOL-1-yl)--oxo-, Methyl](/uploads20/image/exportchempharm/simg_GC11354850_CA11354926/1H-Pyrrolo-2-3-c-PYRIDINE-3-acetic-Acid--4-METHOXY-7--3-Methyl-1H-1-2-4-TRIAZOL-1-yl---oxo---Methyl.jpg)
